Closing the Innovation Gap: Why Drug Discovery Breakthroughs Are Failing to Reach Patients
Why do so many drug discovery breakthroughs fail to reach patients? Trisha Pillay speaks with Christian Nkanga to find out.
Type at least 2 characters to search
Showing results for
Anthropic’s Big AI Drug Discovery Announcement
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.
Artificial Intelligence in Healthcare
Close the Drug Discovery Loop by Leveraging the DMTA Cycle
The DMTA cycle is the engine of modern pharma R&D. Learn how integrated DMTA workflows reduce early-stage attrition and compress drug discovery timelines.
Drug Discovery
Preclinical vs Clinical Research Strategy for Drug Development
Explore the critical differences between preclinical vs clinical research, and how closing the translation gap can reduce drug development attrition and improve R&D decision-making.
Drug Discovery
Modern Drug Discovery Challenges Demand a New Pharma Paradigm
Explore the biggest drug discovery challenges facing pharma today, from translational gaps to AI integration, and why a new pharma paradigm is needed.
Drug Discovery
What 13 Years of Data Shows About Drug Innovation in Psychiatry
From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry
Drug Discovery
Shahid Siddiqui
Founder and CEO, McGenome, LLC
Deepankar Nayak
CEO, Deep Longevity, London, UK
Kimberly S. Clarke
Scientific Council Member – Anchor, Oncology & Advanced Therapeutics
Dr. Claus Bolte
Director and Vice-Chair of committees at University Hospital Basel
No result found for